drugset / Trial / NCT01289509

A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects

NCT01289509

Phase 1 Completed 42 enrolled Eisai Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the relative bioavailability (BA) of two lots of E5501 40 mg tablets administered twice as single oral doses to healthy subjects.

Timeline

Start
2010-12
Primary completion
2011-03
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Avatrombopag Small molecule 40 mg Oral